BR9803300A - Formulação farmacêutica. - Google Patents

Formulação farmacêutica.

Info

Publication number
BR9803300A
BR9803300A BR9803300-0A BR9803300A BR9803300A BR 9803300 A BR9803300 A BR 9803300A BR 9803300 A BR9803300 A BR 9803300A BR 9803300 A BR9803300 A BR 9803300A
Authority
BR
Brazil
Prior art keywords
pharmaceutical formulation
drugs
nsaid
drug
optionally
Prior art date
Application number
BR9803300-0A
Other languages
English (en)
Inventor
Andreas Supersaxo
Original Assignee
Roche Consumer Health Worldwid
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Consumer Health Worldwid filed Critical Roche Consumer Health Worldwid
Publication of BR9803300A publication Critical patent/BR9803300A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof

Abstract

Patente de Invenção: <B>"FORMULAçãO FARMACêUTICA"<D>. A presente invenção refere-se a uma nova formulação farmacêutica para a aplicação tópica de drogas, particularmente as drogas antiinflamatórias não esteroidais (NSAID's), compreendendo: (a) uma quantidade terapeuticamente efetiva de uma droga; (b) tampão de fosfato de sódio; e, opcionalmente, (c) um solvente alcoólico.
BR9803300-0A 1997-04-10 1998-04-08 Formulação farmacêutica. BR9803300A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97105914 1997-04-10

Publications (1)

Publication Number Publication Date
BR9803300A true BR9803300A (pt) 2000-01-11

Family

ID=8226680

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9803300-0A BR9803300A (pt) 1997-04-10 1998-04-08 Formulação farmacêutica.

Country Status (15)

Country Link
US (1) US6420394B1 (pt)
EP (1) EP0872247B1 (pt)
JP (1) JP4580476B2 (pt)
KR (1) KR100554811B1 (pt)
CN (1) CN1191826C (pt)
AR (1) AR012376A1 (pt)
AT (1) ATE243043T1 (pt)
BR (1) BR9803300A (pt)
CA (1) CA2232855C (pt)
DE (1) DE69815585T2 (pt)
DK (1) DK0872247T3 (pt)
ES (1) ES2201361T3 (pt)
PT (1) PT872247E (pt)
TR (1) TR199800631A2 (pt)
ZA (1) ZA982872B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US20090088443A1 (en) * 2002-02-15 2009-04-02 Julius Remenar Novel crystalline forms of conazoles and methods of making and using the same
WO2004060347A2 (en) * 2002-09-03 2004-07-22 Transform Pharmaceuticals, Inc. Pharmaceutical propylene glycol solvate compositions
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
US20050025791A1 (en) * 2002-06-21 2005-02-03 Julius Remenar Pharmaceutical compositions with improved dissolution
AU2003213719A1 (en) 2002-03-01 2003-09-16 Regents Of The University Of Michigan Multiple-component solid phases containing at least one active pharmaceutical ingredient
US20030191187A1 (en) * 2002-04-01 2003-10-09 Lee Fang Yu Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US20060052432A1 (en) * 2002-09-20 2006-03-09 Julius Remenar Pharmaceutical compositions with improved dissolution
US7166641B2 (en) * 2002-10-02 2007-01-23 Yung Shin Pharmaceutical Industrial Co., Ltd. Pharmaceutically acceptable salts containing local anesthetic and anti-inflammatory activities and methods for preparing the same
US20060148877A1 (en) * 2002-11-26 2006-07-06 Transform Pharmaceuticals, Inc. Pharmaceutical formulations of celcoxib
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US7132452B2 (en) * 2003-03-10 2006-11-07 Fang-Yu Lee Topical formulation having effects on alleviating pain/inflammation caused by herpes virus infection
US20050036953A1 (en) * 2003-08-13 2005-02-17 Moshe Arkin Topical compositions of ammonium lactate
US20050037040A1 (en) * 2003-08-13 2005-02-17 Moshe Arkin Topical compositions of urea and ammonium lactate
US20050042182A1 (en) * 2003-08-13 2005-02-24 Moshe Arkin Topical compositions of urea
US20050020552A1 (en) * 2003-07-16 2005-01-27 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050042268A1 (en) * 2003-07-16 2005-02-24 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050025833A1 (en) * 2003-07-16 2005-02-03 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
KR101121890B1 (ko) * 2004-11-05 2012-03-19 리도 케미칼 가부시키가이샤 비스테로이드 소염 진통약을 함유하는 비수계 경피흡수제제
US20070287741A1 (en) * 2006-06-13 2007-12-13 Uri Herzberg Compositions and methods for preventing or reducing postoperative ileus and gastric stasis in mammals
US20080220068A1 (en) * 2006-07-31 2008-09-11 Laboratories Besins International Treatment and prevention of excessive scarring
PL2192907T3 (pl) * 2007-08-16 2018-10-31 Remedor Biomed Ltd. Kompozycje erytropoetyny i fibronektyny do zastosowań terapeutycznych
PL214538B1 (pl) 2009-05-28 2013-08-30 P P F Hasco Lek Spolka Akcyjna Kompozycja liposomowa zawierajaca naproksen i sposób wytwarzania kompozycji liposomowej zawierajacej naproksen
US9056775B2 (en) * 2010-03-12 2015-06-16 Council Of Scientific And Industrial Research Process for the preparation of inorganic hydrogels with alkali halides
US9012402B1 (en) 2014-06-11 2015-04-21 James Blanchard Gel for topical delivery of NSAIDs to provide relief of musculoskeletal pain and methods for its preparation
US10821075B1 (en) 2017-07-12 2020-11-03 James Blanchard Compositions for topical application of a medicaments onto a mammalian body surface
KR20190101140A (ko) * 2018-02-22 2019-08-30 동아제약 주식회사 비스테로이드성 소염진통 활성성분을 함유하는 필름 형성 약제학적 조성물
CA3127881A1 (en) * 2019-01-29 2020-08-06 Bayer Healthcare Llc Topical gel compositions of naproxen

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5829706A (ja) * 1981-08-14 1983-02-22 Toko Yakuhin Kogyo Kk 消炎鎮痛外用剤
JPS6253933A (ja) * 1985-09-02 1987-03-09 Nitto Electric Ind Co Ltd 外皮投与用組成物
JPH085800B2 (ja) * 1986-12-19 1996-01-24 エーザイ株式会社 塩化リゾチ−ム及びグリチルリチン酸ジカリウム含有水溶液製剤
US4720353A (en) * 1987-04-14 1988-01-19 Richardson-Vicks Inc. Stable pharmaceutical w/o emulsion composition
US5183829A (en) * 1991-09-27 1993-02-02 Applied Analytical Industries, Inc. Oral liquid compositions of non-steroidal anti-inflammatory drugs
WO1994002176A1 (en) * 1992-07-28 1994-02-03 The Procter & Gamble Company Pharmaceutical composition for topical use containing a crosslinked cationic polymer and an alkoxylated ether
CA2153234C (en) * 1993-04-16 1999-02-16 Masanobu Takeuchi Aqueous drug composition having property of reversible thermosetting gelation
JPH09500901A (ja) * 1993-07-28 1997-01-28 インサイト・ビジョン・インコーポレイテッド 薬剤供給用懸濁液
JPH07223942A (ja) * 1994-02-03 1995-08-22 Ildong Pharm Co Ltd プロピオン酸系非ステロイド性薬物を有効成分として含有する新規消炎鎮痛外用ゲル製剤
CN1106259A (zh) * 1994-02-05 1995-08-09 日东制药株式会社 含有作为有效成分的丙酸类非类固醇性药物的新颖消炎镇痛外用凝胶制剂
DE69528165T2 (de) * 1994-04-21 2003-05-15 Hisamitsu Pharmaceutical Co Transdermal verabreichbare grundlage und daraus hergestelltes transdermal verabreichbares arzneimittel
IT1275955B1 (it) * 1995-03-22 1997-10-24 Dompe Spa Formulazioni farmaceutiche in forma di gel tissotropico
JPH0967272A (ja) * 1995-08-31 1997-03-11 Advanced Sukin Res Kenkyusho:Kk 局所適用組成物
GB9626513D0 (en) * 1996-12-20 1997-02-05 Bioglan Ireland R & D Ltd A pharmaceutical composition
CN1252003A (zh) * 1997-03-31 2000-05-03 强生消费者公司 增强药物化合物渗透作用的溶剂系统

Also Published As

Publication number Publication date
CA2232855C (en) 2007-10-09
CN1191826C (zh) 2005-03-09
TR199800631A3 (tr) 1998-10-21
JPH10287588A (ja) 1998-10-27
CN1195524A (zh) 1998-10-14
DE69815585T2 (de) 2004-04-29
DE69815585D1 (de) 2003-07-24
KR19980081238A (ko) 1998-11-25
TR199800631A2 (xx) 1998-10-21
EP0872247B1 (en) 2003-06-18
US6420394B1 (en) 2002-07-16
ES2201361T3 (es) 2004-03-16
DK0872247T3 (da) 2003-09-29
ZA982872B (en) 1998-10-12
PT872247E (pt) 2003-10-31
ATE243043T1 (de) 2003-07-15
CA2232855A1 (en) 1998-10-10
JP4580476B2 (ja) 2010-11-10
AR012376A1 (es) 2000-10-18
EP0872247A1 (en) 1998-10-21
KR100554811B1 (ko) 2006-05-25

Similar Documents

Publication Publication Date Title
BR9803300A (pt) Formulação farmacêutica.
ES2192234T3 (es) Composiciones farmaceuticas parenterales conteniendo sales de amonioalquilo de acidos 2-arilpropionicos.
BR9909565A (pt) Derivados bicìclicos do ácido hidroxâmico
ES2145913T3 (es) Inhibidores de metaloproteasas.
BR9813947A (pt) Composições tópicas para distribuição de droga nsai
RU94032150A (ru) Лекарственное средство с замедленным высвобождением активно-действующего вещества
FI962735A0 (fi) 2-hydroksi-5-fenylatsobensoehapon johdannaisten käyttö paksusuolen syövän kemialliseen ehkäisyyn ja kemoterapeuttisena aineena
BR9912694A (pt) Composto para preparar medicamento de administração pulmonar
BR9607862A (pt) Composição farmacêutica filmogênica para administração transdérmica
CA2191789A1 (fr) Composes biaromatiques portant un groupement adamantyl en ortho, compositions pharmaceutiques et cosmetiques les contenant et utilisations de ces compositions
BR9709062A (pt) Composto, composição farmacêutica, e, uso de um composto.
BR9916575A (pt) Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa
BR9908458A (pt) Tiolésteres de ácido 11beta-benzaldoxim-estra-4,9-dien-carbÈnico substituìdos por s, processos para a sua preparação e preparados farmacêuticos contendo estes compostos
BR9811458A (pt) &#34;sistema solvente para penetração melhorada de compostos farmacêuticos&#34;
SE9401005L (sv) Farmaceutisk komposition med analgetisk aktivitet
BR9915123A (pt) Composição de uma substância farmaceuticamente ativa e dispensador
ATE253359T1 (de) Antithrombotische mittel
BR0013582A (pt) Agonistas retinóides seletivos para rar
BRPI0407438A (pt) Sistema terapêutico compreendendo amoxicilina e ácido clavulânico
ATE286395T1 (de) Antithrombotische mittel
BR9811954A (pt) ácidos 3-aril-succinamido-hidroxâmicos, processos para sua produção e preparações farmacêuticas contendo estas substâncias
BR9810387A (pt) (s) 3, 4, 5-trimetoxibenzoato de 2-metilamino-2-fenil-n-butila, e sua aplicação para o tratamento de dor crÈnica
PT927031E (pt) Composicao farmaceutica que contem nimesulide para administracao por via oral
DE60112578D1 (de) Pharmazeutische diclofenac-verbindung basierend auf vitamin e, papain und hyaluronidase
BR9710629A (pt) Composi-Æo farmac-utica processo para sua prepara-Æo composto para utiliza-Æo como agente terap-utico e utiliza-Æo e utiliza-Æo de um composto

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: ROCHE CONSUMER HEALTH AG (CH)

Free format text: ALTERADO DE: ROCHE CONSUMER HEALTH (WORLDWIDE) S.A.

B25G Requested change of headquarter approved

Owner name: ROCHE CONSUMER HEALTH AG (CH)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020050051214/RJ DE 14/06/2005.

B25D Requested change of name of applicant approved

Owner name: BAYER CONSUMER CARE AG (CH)

Free format text: ALTERADO DE: ROCHE CONSUMER HEALTH AG

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time